GW Pharmaceuticals to Present at the Leerink Partners 6th Annual Global Healthcare Conference on 15 February

Date : 02/08/2017 @ 12:14PM
Source : GlobeNewswire Inc.
Stock : GW Pharmaceuticals Plc ADS (MM) (GWPH)
Quote : 122.55  0.0 (0.00%) @ 8:10AM

GW Pharmaceuticals to Present at the Leerink Partners 6th Annual Global Healthcare Conference on 15 February

GW PHARMACEUTICALS PLC (NASDAQ:GWPH)
Historical Stock Chart

1 Year : From Dec 2016 to Dec 2017

Click Here for more GW PHARMACEUTICALS PLC Charts.

GW Pharmaceuticals plc (Nasdaq:GWPH) (“GW” or “the Company”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, today announced that Justin Gover, GW’s Chief Executive Officer, will present at the Leerink Partners 6th Annual Global Healthcare Conference on Wednesday, February 15, 2017 at 2:00 p.m. EST at the Lotte New York Palace, New York City.  

A live audio webcast of the presentation will be available through GW’s corporate website at www.gwpharm.com in the Investors section under Events & Presentations. A replay will be available soon after the live presentation.

About GW Pharmaceuticals plc

Founded in 1998, GW is a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform in a broad range of disease areas. GW is advancing an orphan drug program in the field of childhood epilepsy with a focus on Epidiolex® (cannabidiol), which is in Phase 3 clinical development for the treatment of Dravet syndrome, Lennox-Gastaut syndrome, Tuberous Sclerosis Complex and Infantile Spasms. GW commercialized the world’s first plant-derived cannabinoid prescription drug, Sativex® (nabiximols), which is approved for the treatment of spasticity due to multiple sclerosis in 31 countries outside the United States. The Company has a deep pipeline of additional cannabinoid product candidates which includes compounds in Phase 1 and 2 trials for glioma, schizophrenia and epilepsy. For further information, please visit www.gwpharm.com.

Enquiries:

GW Pharmaceuticals plc	
Stephen Schultz, VP Investor Relations (U.S.)
917 280 2424 / 401 500 6570

Latest GWPH Messages

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts


Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.


NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.